Dyadic International Updates on Business Progress Amid Growing Focus on Alternative Proteins and Global Health Solutions’
JUPITER, Fla. September 23, 2024’ Dyadic International, Inc. (NASDAQ: DYAI), a biotechnology company centered on the large-scale manufacture of proteins for various applications, has provided an update on its business endeavors while announcing its attendance at the Bioprocess International Conference in Boston from September 23-26, 2024. The company specializes in producing proteins for non-pharmaceutical uses, including food, nutrition, wellness, and animal and human health therapeutics and vaccines.
In its recent update, Dyadic highlighted its ongoing commitment to developing innovative solutions in the alternative protein sector. This aligns with the growing demand for plant-based and alternative protein sources as consumer preferences shift towards sustainable and health-conscious options. The company’s large-scale bioproduction capabilities place it at a strategic advantage in this expanding industry.
Additionally, Dyadic has reinforced its collaboration with the Israel Institute for Biological Research (IIBR). Announced in February 2024, the partnership focuses on addressing bio-threats and emerging diseases through advanced microbial platforms for protein development. This collaboration aims to leverage Dyadic’s expertise in protein bioproduction with IIBR’s capabilities in antibody and antigen discovery, striving to create effective treatments and vaccines for global health challenges.
Both entities are committed to innovating solutions that could potentially lead to commercialization through collaborative out-licensing initiatives, although it is noted that this framework remains non-binding, pending a formal agreement.
The dual focus on alternative proteins and global health solutions positions Dyadic as a proactive player in two critical sectors one that addresses sustainability and health trends in consumer food products, and another that aims to tackle urgent healthcare challenges.
As Dyadic continues to develop its strategies and partnerships, its presence at the upcoming Bioprocess International Conference highlights its commitment to discussing and showcasing advancements in bioprocessing technologies, crucial for both the alternative protein market and therapeutic applications.
Comments